Abstract Library

#4283 Long-term efficacy and safety of peptide receptor radionuclide therapy (PRRT) in Japanese patients with unresectable neuroendocrine tumour: Japanese phase I and phase I/II extension study

Introduction: PRRT with 177Lu-DOTATATE has been approved in Japan according to Japanese phase I and Phase I/II clinical trials. Primary end point of these clinical studies was safety and response rate, therefore, long-term efficacy and safety of PRRT for Japanese patients with NET are uncertain.

Conference:

Presenting Author: Ichikawa Y

Authors: Kobayashi N, Ono H, Okubo N, Akahoshi K, Kudo A,

Keywords: Neuroendocrine tumour, Peptide receptor radionuclide therapy, Japanese patients,

#3668 Factors contributing to tumor shrinkage after peptide receptor radionuclide therapy in patients with unresectable neuroendocrine tumors

Introduction: Peptide receptor activation therapy (PRRT) is a promising treatment option for metastatic neuroendocrine tumors (NETs). However, predicting tumor shrinkage before treatment is challenging.

Conference:

Presenting Author:

Authors: Noritoshi K, Sho H, Wild D, Kaul F, Motokazu S,

Keywords: lesion-based analysis, neuroendocrine tumor, peptide receptor radionuclide therapy,

#3351 Safety and efficacy of peptide receptor radionuclide therapy with 177 Lu-DOTA 0-Tyr 3-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors

Introduction: Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTA0-Tyr3-octreotate (177Lu-DOTATATE) is one of the most reliable treatments for unresectable, progressive neuroendocrine tumors (NETs) with somatostatin receptor expression.

Conference:

Presenting Author:

Authors: Kobayashi N, Takano S, Ito K, Sugiura M, Ogawa M,

Keywords: Peptide receptor radionuclide therapy, 177Lu-DOTA0-Tyr3-octreotate, neuroendocrine tumor,

#2121 Phase II Study of Temozolomide Monotherapy in Patients of Neuroendocrine Carcinoma with Resistant to Platinum-Based Chemotherapy

Introduction: Neuroendocrine carcinomas (NEC) (high grade Ki67 > 20%) were poor prognostic and lethal disease. Platinum-based chemotherapy is usually chosen as a first line treatment for advanced NEC, however, this efficacy is temporary and there is no standard second-line treatment yet. Temozolomide is a good candidate, however it was not approved for NEC by Japanese authorities.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Ichikawa Y, Kobayashi N, Tokuhisa M, Goto A, Hiroshima Y,

Keywords: Neuroendocrine Carcinoma, Temozolomide,

#1788 Prospective Observational Study 1 on the Prognosis of Patients with Unresectable Advanced Gastrointestinal and Pancreatic Neuroendocrine Tumors (PROP-UP 1 Study) in Japan

Introduction: No previous observational studies on the prognosis of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) [pancreatic neuroendocrine neoplasms (PNENs) and gastrointestinal neuroendocrine neoplasms (GI-NENs)] exist in Japan.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Toriyama K, Hijioka S, Komoto I, Kobayashi N, Okusaka T,

Keywords: prop-up, japan, gep-nen,